The effect of aspartate β-hydroxylase inhibition on cancer immunotherapy

abstrakt v elektronické podobě
Creative Commons License IconCreative Commons BY Icon
en
Thumbnail
File can be accessed.Získat publikaci
Autor
Johari, Shweta DilipORCiD Profile - 0000-0001-6265-8949WoS Profile - ILO-5336-2023Scopus Profile - 57222993686
Krausová, KateřinaORCiD Profile - 0009-0002-4812-8380WoS Profile - DAO-3282-2022Scopus Profile - 7801502020
Žucha, BarboraORCiD Profile - 0009-0004-9398-7381WoS Profile - CLJ-4905-2022Scopus Profile - 57351757500
Madureira Trufen, Carlos Eduardo
Poláková, IngridORCiD Profile - 0000-0003-1315-0924WoS Profile - I-9355-2014Scopus Profile - 24766742200
Olsen, Mark
Šmahel, MichalORCiD Profile - 0000-0002-0366-4932WoS Profile - H-4317-2017Scopus Profile - 6701604039
CCL-CONFERENCE CZECHOSLOVAKIA LTD.

Datum vydání
2024
Publikováno v
Neuveden
Metadata
Zobrazit celý záznam
Kolekce
Abstrakt
Aspartate β-hydroxylase (ASPH) is overexpressed in 70-90% of various solid tumors, contributing to tumor cell proliferation, migration, and invasion. In addition, recombinant ASPH inhibits natural killer (NK) cells, but an effect on other immune cells has not been described. Small molecule inhibitors have been developed to target tumors overexpressing ASPH. In this study, we combined ASPH inhibition with immunotherapy to enhance cancer therapy and seek out affected immune cells.
Klíčová slova
aspartate β-hydroxylase, immunotherapy, ASPH inhibitor, Elispot assay
Trvalý odkaz
https://hdl.handle.net/20.500.14178/2644
Licence

Licence pro užití plného textu výsledku: Creative Commons Uveďte původ 4.0 International

Zobrazit podmínky licence